Regulatory Q&A Forum
Ask questions, share knowledge, and get help from the regulatory community
For medical device startups targeting the European market, securing a Person Responsible for Regulatory Compliance (PRRC) is a mandatory step under the EU MDR. When outsourcing this role, how can a st...
For non-EU companies aiming to maintain or gain access to the European market, the REACH regulation requires the appointment of an Only Representative (OR) to manage registration and compliance obliga...
With significant updates to chemical regulations on the horizon, such as the proposed restrictions on per- and polyfluoroalkyl substances (PFAS) under REACH, how should non-EU medical device manufactu...
As non-EU providers of AI systems prepare for the implementation of the EU AI Act, a critical operational step is the appointment of an EU-based Authorized Representative (AR). A common question is ab...
With the EU AI Act set to establish new compliance obligations for artificial intelligence systems placed on the European market, how should a non-EU provider of a high-risk AI system navigate the pro...
When medical device manufacturers evaluate potential EU Authorized Representatives (ARs) under the Medical Device Regulation (MDR), how can they move beyond comparing simple annual retainer fees to co...
With the implementation of the Modernization of Cosmetics Regulation Act (MoCRA), what are the specific requirements for designating an FDA U.S. Agent for foreign cosmetic facilities? Under MoCRA, an...
With the implementation of the Modernization of Cosmetics Regulation Act (MoCRA), foreign cosmetic product facilities must now designate a United States agent. This agent serves as the FDA's primary p...
What factors determine the annual cost for an FDA U.S. Agent service? Foreign establishments marketing medical devices in the United States are required by regulation to designate a U.S. Agent, who s...
How should a medical device manufacturer evaluate a "PRRC as a Service" provider's capability to manage evolving European vigilance reporting requirements? As regulatory expectations for post-market s...
When budgeting for an outsourced Person Responsible for Regulatory Compliance (PRRC) under the EU MDR, manufacturers must look beyond a single price tag and instead analyze the key factors that determ...
When medical device manufacturers budget for EU MDR compliance, how can they accurately estimate the annual cost of contracting a "Person Responsible for Regulatory Compliance (PRRC) as a Service," co...
For non-EU manufacturers preparing for the comprehensive REACH restrictions on Per- and Polyfluoroalkyl Substances (PFAS), what is a robust framework for selecting a qualified Only Representative (OR)...
Given the increasing regulatory pressure on per- and polyfluoroalkyl substances (PFAS) under the EU REACH regulation, particularly with the European Chemicals Agency (ECHA) advancing its universal res...
For non-EU companies, including medical device manufacturers, placing products on the European market often requires compliance with the REACH (Registration, Evaluation, Authorisation and Restriction ...
When developing a premarket submission for a Class II software-enabled device, such as a wearable cardiac monitor, sponsors must navigate a complex set of regulatory expectations. Beyond demonstrating...
For a sponsor developing a novel Class II in vitro diagnostic (IVD) device, what is the most effective way to integrate FDA's Special Controls into the product development lifecycle and 510(k) submiss...
How should sponsors of connected medical devices effectively integrate cybersecurity management into their existing Quality Management System (QMS) to align with FDA's expectations for total product l...
With the Modernization of Cosmetics Regulation Act (MoCRA) mandating that foreign cosmetic facilities designate a U.S. Agent, many companies are evaluating the associated costs. However, focusing sole...
Given the requirement under the Modernization of Cosmetics Regulation Act (MoCRA) for foreign cosmetic facilities to designate a U.S. Agent, what key criteria should be used to evaluate and select the...